Company Overview
QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems that utilize low frequency sound waves for the detection, diagnosis, monitoring, and treatment of diseases both in the United States and internationally, with a specific product offering including the QT Breast Scanner. The company operates within the Healthcare sector, specifically targeting the Medical Devices industry, where it focuses on advancing diagnostic technologies rather than providing broad consumer healthcare services. This entity operates at a scale defined by a market capitalization of $74.06M and reported annual revenue of $18.93M, while the total employee count is not publicly disclosed in available records. These valuation and revenue figures indicate that QT Imaging is a small-cap entity with a relatively modest revenue base, suggesting it is likely an early-stage or specialized manufacturer rather than a large-scale diversified medical conglomerate, which often correlates with higher business risk and significant volatility in its stock price.
Financial Health
The company reported a revenue of $18.93M for the trailing twelve months, yet this revenue generated a net income of $-21,083,000 and an EBITDA of $-4,306,000, revealing a severe structural disconnect where operating costs and expenses significantly exceed gross profit margins. The free cash flow stands at $-8,546,715, which indicates that the company is currently burning through its liquid assets, thereby limiting its financial flexibility to fund operations without securing additional external financing. Analyzing the profitability margins reveals a Gross Margin of 45.4%, which suggests that the cost of goods sold is well-controlled relative to sales, yet this is overwhelmed by an Operating Margin of -8.5% and a Profit Margin of -111.4%, indicating substantial overhead burdens or R&D expenses that have yet to be offset by earnings. Regarding liquidity and leverage, the company holds $10.41M in cash against $5.24M in debt, resulting in a Debt to Equity ratio of 81.36, which implies a highly leveraged balance sheet relative to shareholders' equity despite the absolute debt amount being lower than cash reserves. The Current Ratio is recorded at 2.81, which indicates a strong short-term liquidity position where current assets are more than double current liabilities, providing a buffer against immediate obligations. Furthermore, the Return on Equity is N/A due to the negative equity base, while the Return on Assets is -19.1%, revealing that the management team is currently unable to generate positive returns on the capital deployed into the business assets.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E is also N/A, which implies that the market cannot value the stock based on traditional earnings multiples because the company has not yet generated positive net income to support such a calculation. The price-to-book ratio is 13.07, which indicates that the market is pricing the company at a significant premium over its book value, a common characteristic for biotech or medical device firms with high potential but currently negative earnings. Additionally, the price-to-sales ratio is 3.91 and the EV/EBITDA is -18.38, suggesting that valuation is driven primarily by revenue growth expectations rather than profitability or cash flow generation. The stock has demonstrated extreme price volatility, trading between a 52-week high of $46.05 and a 52-week low of $4.90, meaning the current price sits at a level that reflects a massive expansion from the low but is significantly below the recent peak. The Beta is -0.11, which is an anomalous metric for a public equity, suggesting an inverse correlation to the broader market or significant data irregularities, but strictly speaking, it indicates a lack of standard positive volatility relative to the market index.
Growth & Income
The revenue growth year-over-year is 877.6%, while earnings growth is N/A, indicating that the company is in a phase of rapid top-line expansion where profitability has not yet materialized to match the speed of sales growth. Because the company has not established a positive earnings base, there is no dividend yield or payout ratio to evaluate for sustainability; consequently, QT Imaging reinvests any available resources into research and development or operational scaling rather than distributing cash to shareholders. This growth-focused profile is typical for companies in the medical device sector that prioritize product commercialization and market penetration over immediate shareholder returns. Overall, the company presents a high-risk, high-reward income profile characterized by explosive revenue scaling but a complete absence of current profitability or dividend income for investors seeking regular cash distributions.